Cargando…
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
BACKGROUND: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffecti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012564/ https://www.ncbi.nlm.nih.gov/pubmed/29942666 http://dx.doi.org/10.1136/esmoopen-2018-000375 |
_version_ | 1783333937808932864 |
---|---|
author | Fumet, Jean-David Isambert, Nicolas Hervieu, Alice Zanetta, Sylvie Guion, Jean-Florian Hennequin, Audrey Rederstorff, Emilie Bertaut, Aurélie Ghiringhelli, Francois |
author_facet | Fumet, Jean-David Isambert, Nicolas Hervieu, Alice Zanetta, Sylvie Guion, Jean-Florian Hennequin, Audrey Rederstorff, Emilie Bertaut, Aurélie Ghiringhelli, Francois |
author_sort | Fumet, Jean-David |
collection | PubMed |
description | BACKGROUND: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX) increases treatment efficacy. METHODS: This phase II study (ClinicalTrials.gov NCT03202758) will assess the efficacy and safety of FOLFOX/D/T association in patients with mCRC (n=48). Good performance status patients (Eastern Cooperative Oncology Group <2) with untreated, RAS mutational status mCRC will be eligible. Prior adjuvant therapy is allowed provided recurrence is >6 months postcompletion. There is a safety lead in nine patients receiving FOLFOX/D/T. Assuming no safety concerns the study will go on to include 39 additional patients. Patients will receive folinic acid (400 mg/m²)/5-fluorouracil (400 mg/m² as bolus followed by 2400 mg/m(2) as a 46-hour infusion)/oxaliplatin (85 mg/m(2)) every 14 days with D (750 mg) D1 every 14 days and T (75 mg) D1 every 28 days. After six cycles of FOLFOX only D/T will continue until disease progression, death, intolerable toxicity, or patient/investigator decision to stop. Primary endpoint is safety and efficacy according to progression-free survival (PFS); secondary endpoints include overall response rate and quality of life. Hypothesis is that a PFS of 50% at 6 months is insufficient and a PFS of 70.7% is expected (with α=10%, β=10%). Blood, plasma and tumour tissue will be collected and assessed for potential prognostic and predictive biomarkers. |
format | Online Article Text |
id | pubmed-6012564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-60125642018-06-25 Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer Fumet, Jean-David Isambert, Nicolas Hervieu, Alice Zanetta, Sylvie Guion, Jean-Florian Hennequin, Audrey Rederstorff, Emilie Bertaut, Aurélie Ghiringhelli, Francois ESMO Open Protocol BACKGROUND: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX) increases treatment efficacy. METHODS: This phase II study (ClinicalTrials.gov NCT03202758) will assess the efficacy and safety of FOLFOX/D/T association in patients with mCRC (n=48). Good performance status patients (Eastern Cooperative Oncology Group <2) with untreated, RAS mutational status mCRC will be eligible. Prior adjuvant therapy is allowed provided recurrence is >6 months postcompletion. There is a safety lead in nine patients receiving FOLFOX/D/T. Assuming no safety concerns the study will go on to include 39 additional patients. Patients will receive folinic acid (400 mg/m²)/5-fluorouracil (400 mg/m² as bolus followed by 2400 mg/m(2) as a 46-hour infusion)/oxaliplatin (85 mg/m(2)) every 14 days with D (750 mg) D1 every 14 days and T (75 mg) D1 every 28 days. After six cycles of FOLFOX only D/T will continue until disease progression, death, intolerable toxicity, or patient/investigator decision to stop. Primary endpoint is safety and efficacy according to progression-free survival (PFS); secondary endpoints include overall response rate and quality of life. Hypothesis is that a PFS of 50% at 6 months is insufficient and a PFS of 70.7% is expected (with α=10%, β=10%). Blood, plasma and tumour tissue will be collected and assessed for potential prognostic and predictive biomarkers. BMJ Publishing Group 2018-06-19 /pmc/articles/PMC6012564/ /pubmed/29942666 http://dx.doi.org/10.1136/esmoopen-2018-000375 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Protocol Fumet, Jean-David Isambert, Nicolas Hervieu, Alice Zanetta, Sylvie Guion, Jean-Florian Hennequin, Audrey Rederstorff, Emilie Bertaut, Aurélie Ghiringhelli, Francois Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title_full | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title_fullStr | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title_full_unstemmed | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title_short | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer |
title_sort | phase ib/ii trial evaluating the safety, tolerability and immunological activity of durvalumab (medi4736) (anti-pd-l1) plus tremelimumab (anti-ctla-4) combined with folfox in patients with metastatic colorectal cancer |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012564/ https://www.ncbi.nlm.nih.gov/pubmed/29942666 http://dx.doi.org/10.1136/esmoopen-2018-000375 |
work_keys_str_mv | AT fumetjeandavid phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT isambertnicolas phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT hervieualice phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT zanettasylvie phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT guionjeanflorian phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT hennequinaudrey phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT rederstorffemilie phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT bertautaurelie phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer AT ghiringhellifrancois phaseibiitrialevaluatingthesafetytolerabilityandimmunologicalactivityofdurvalumabmedi4736antipdl1plustremelimumabantictla4combinedwithfolfoxinpatientswithmetastaticcolorectalcancer |